VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

VolitionRx (NYSE AMERICAN: VNRX) will host its first quarter 2026 earnings and business update conference call on Friday, May 15, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. CET).

Rhea-AI Summary

VolitionRx (NYSE AMERICAN: VNRX) will host its first quarter 2026 earnings and business update conference call on Friday, May 15, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. CET). Senior management will review financial and operating results, key events, and upcoming milestones, with live webcast and replay available.

Argus May 11 session

-8.89% close to close Open Argus

Details

News Market Reaction – VNRX

In the May 11 session, VNRX declined 8.89%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -8.9% in the session following this news. A negative reaction despite a routine earn...

Analysis

The stock moved -8.9% in the session following this news. A negative reaction despite a routine earnings call scheduling fits a broader picture of weakness, with VNRX trading at $2.25, about 88.03% below its 52-week high. Historically, similar “conferences,earnings” announcements averaged only a 0.35% move, so a larger decline could reflect sensitivity to balance-sheet and listing risks, as well as potential overhang from 17,968,090 registered resale shares under the effective S-3.

Key Figures

Conference date: Friday, May 15, 2026 Call time (US): 8:30 a.m. U.S. Eastern Time Call time (EU): 2:30 p.m. Central European Time +5 more

Conference date

Friday, May 15, 2026

Q1 2026 earnings and business update call

Call time (US)

8:30 a.m. U.S. Eastern Time

Start time for Q1 2026 earnings call

Call time (EU)

2:30 p.m. Central European Time

European time for Q1 2026 earnings call

Conference ID

13760656

Access code for Q1 2026 earnings conference call

Replay end date

May 29, 2026

Telephone replay available until this date

Current price

$2.25

Pre-news trading level vs 52-week range

1-day move

-7.02%

Price change over the last 24 hours before this news

Shelf shares registered

17,968,090 shares

Common stock registered for resale under S-3 shelf

Previous Conferences,earnings Reports

5 past events · Latest: Mar 25

Same Type 5 events

1. Mar 25

   Earnings call scheduled

   24h Move

   +0.9%

   Announced timing and access details for FY 2025 results call.

2. Nov 10

   Earnings call scheduled

   24h Move

   +0.6%

   Scheduled Q3 2025 earnings and business update conference call.

3. Aug 08

   Earnings call scheduled

   24h Move

   +0.5%

   Set date and time for Q2 2025 earnings and update call.

4. May 12

   Earnings call scheduled

   24h Move

   -1.0%

   Announced Q1 2025 earnings call with management participation details.

5. Mar 25

   Earnings call scheduled

   24h Move

   +0.9%

   Outlined logistics for FY 2024 earnings and business update call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern Time

HENDERSON, Nev., May 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, May 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2026 and to provide a business update. Details of this event can be found below.

Event: VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call

Date:  Friday, May 15, 2026

Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID:   13760656

Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter 2026, subsequent events and upcoming milestones.

A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until May 29, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13760656.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-first-quarter-2026-earnings-conference-call-and-business-update-302768143.html

SOURCE VolitionRx Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is VolitionRx (VNRX) holding its Q1 2026 earnings conference call?

VolitionRx will hold its Q1 2026 earnings and business update call on Friday, May 15, 2026 at 8:30 a.m. U.S. Eastern Time. According to Volition, the call will cover financial results, recent events, subsequent developments, and upcoming corporate milestones.

How can investors join the VolitionRx (VNRX) Q1 2026 earnings call by phone?

Investors can join by dialing 1-877-407-9716 (U.S. & Canada toll-free), 0 800 756 3429 (U.K. toll-free), or 1-201-493-6779 (international). According to Volition, participants should use Conference ID 13760656 to access the first quarter 2026 earnings call.

Will there be a replay of the VolitionRx (VNRX) Q1 2026 earnings conference call?

Yes, a telephone replay will be available until May 29, 2026. According to Volition, investors can access it by dialing 1-844-512-2921 (U.S. & Canada toll-free) or 1-412-317-6671 (international) and entering replay pin 13760656.

Who is hosting the VolitionRx (VNRX) first quarter 2026 earnings and business update call?

The call will be hosted by Louise Batchelor, Group Chief Marketing & Communications Officer. According to Volition, she will be joined by Cameron Reynolds, President and Group CEO, and Terig Hughes, Group CFO, to discuss Q1 2026 results and milestones.

What topics will be covered on the VolitionRx (VNRX) Q1 2026 earnings conference call?

The call will cover financial and operating results for Q1 2026, important events during the quarter, subsequent events, and upcoming milestones. According to Volition, management will provide a broader business update alongside the quarterly earnings discussion.

Is there an audio webcast for the VolitionRx (VNRX) Q1 2026 earnings call?

Yes, a live audio webcast of the first quarter 2026 earnings and business update call will be available via an online link. According to Volition, this offers an alternative to telephone dial-in for investors and analysts following VNRX.